POLR3H Antibody

What is POLR3H and why is it important in research?

POLR3H (also known as RPC8) is the 22.9 kDa subunit of RNA polymerase III (Pol III), a DNA-dependent RNA polymerase that catalyzes the transcription of DNA into RNA using ribonucleoside triphosphates as substrates . POLR3H functions as a specific peripheral component of RNA polymerase III, which synthesizes small RNAs including 5S rRNA and tRNAs . Recent research has highlighted POLR3H's significance in maintaining active chromatin architecture and facilitating transcription of nearby mRNA genes, making it an important target for studying RNA polymerase regulation and function .

What are the molecular characteristics of POLR3H protein?

POLR3H has the following molecular characteristics:

The discrepancy between calculated (20 kDa) and observed (25-30 kDa) molecular weight is likely due to post-translational modifications .

What are the validated applications for POLR3H antibodies?

POLR3H antibodies have been validated for several laboratory applications:

Researchers should note that optimal dilutions may vary depending on sample type and experimental conditions, making antibody titration necessary for each testing system .

How should POLR3H antibody be stored and handled for optimal performance?

POLR3H antibodies should be stored at -20°C where they remain stable for approximately one year after shipment . The antibodies are typically supplied in liquid form in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide with pH 7.3 . For small volume antibodies (20μl sizes), some formulations may contain 0.1% BSA. Importantly, aliquoting is generally unnecessary for -20°C storage, which simplifies laboratory handling procedures .

What positive controls are recommended for validating POLR3H antibody specificity?

Based on validation data, the following positive controls are recommended for different applications:

Using these validated positive controls provides confidence in antibody performance and helps distinguish true signals from background noise .

Why do antibodies against POLR3H show discrepancies between detection methods?

Research has revealed significant discrepancies in POLR3H antibody detection between different methodologies. In one study examining autoantibodies in scleroderma patients, immunoprecipitation detected anti-POLR3H antibodies in 91% of samples, while peptide-based detection (PhIP-Seq) identified only 22% of these same samples . This 29% agreement (kappa = 0.04, P = 0.215) suggests that most anti-POLR3H antibodies recognize conformational epitopes rather than linear peptide sequences . This has important implications for selecting detection methods, as techniques preserving protein conformation may provide more sensitive detection of POLR3H antibodies.

How do I interpret multiple bands or unexpected molecular weights in POLR3H Western blots?

When interpreting Western blot results with POLR3H antibodies, consider:

• The expected observed molecular weight range is 25-30 kDa, which differs from the calculated weight of 20 kDa due to post-translational modifications

• Multiple bands may represent:

  • Different isoforms of POLR3H

  • Post-translationally modified variants

  • Degradation products

  • Non-specific binding

To distinguish between these possibilities, researchers should:

• Include appropriate positive controls (e.g., HeLa cell lysate)

• Perform blocking peptide competition assays to confirm specificity

• Consider using multiple antibodies targeting different epitopes of POLR3H

• Validate findings with complementary techniques such as mass spectrometry

How can POLR3H antibodies be used to study autoimmunity in scleroderma?

POLR3H antibodies have emerged as important tools in studying autoimmunity, particularly in scleroderma patients with anti-RNA polymerase III (POLR3) autoantibodies. Research has revealed that while anti-POLR3A antibodies are commonly used to identify these patients, epitope spreading within the POLR3 complex leads to autoantibodies against multiple subunits .

Specifically, immunoprecipitation studies have demonstrated that 91% of patients with anti-POLR3A antibodies also develop antibodies against POLR3H, making it a highly prevalent target in this autoimmune response . These findings suggest intramolecular epitope spreading occurs within the POLR3 complex, similar to patterns observed with other autoantigens like RNPC3 and PDCD7 .

For researchers studying scleroderma, incorporating POLR3H antibody detection provides a more comprehensive assessment of the autoimmune response against the POLR3 complex, potentially improving diagnostic sensitivity and providing insights into disease mechanisms.

What role does POLR3H play in cross-regulatory mechanisms between RNA polymerases?

Recent research using precision nuclear run-on sequencing (PRO-Seq) and other advanced genomic techniques has revealed that POLR3H, as part of RNA polymerase III, participates in important cross-regulatory mechanisms affecting gene expression .

The data supports a model where RNA polymerase III (containing POLR3H) affects:

• Local chromatin structures

• The FACT (Facilitates Chromatin Transcription) complex

• RNA polymerase II activity on nearby genes

Specifically, depletion of RNA polymerase III leads to changes in nucleosome stability and FACT recruitment, subsequently altering the transcription rate of nearby mRNA genes transcribed by RNA polymerase II . This suggests that POLR3H-containing complexes help maintain active chromatin architecture beyond their direct role in transcribing small RNAs.

Researchers investigating transcriptional regulation should consider these cross-regulatory effects when interpreting results from RNA polymerase perturbation experiments.

What are the best practices for using POLR3H antibodies in chromatin immunoprecipitation (ChIP) studies?

While standard ChIP protocols can be adapted for POLR3H, researchers should consider:

• Crosslinking optimization: Standard 1% formaldehyde for 10 minutes may be sufficient, but optimization might be necessary

• Sonication conditions: Aim for chromatin fragments of 200-500 bp

• Antibody amounts: Start with 2-5 μg of POLR3H antibody per ChIP reaction

• Appropriate controls:

  • Input DNA control

  • IgG negative control

  • Positive control regions (tRNA genes or 5S rRNA genes)

  • Negative control regions (inactive gene deserts)

Recent studies have successfully employed POLR3H antibodies in ChIP-Seq experiments to study cross-regulatory effects between different RNA polymerases . When coupled with other genomic approaches like ATAC-Seq and PRO-Seq, ChIP-Seq with POLR3H antibodies provides valuable insights into the mechanisms of transcriptional regulation.

How do different fixation methods affect POLR3H detection in immunofluorescence applications?

For optimal immunofluorescence detection of POLR3H:

• Fixation options:

  • 4% paraformaldehyde (10-15 minutes): Preserves morphology but may reduce epitope accessibility

  • Methanol/acetone (5-10 minutes at -20°C): Enhances nuclear protein detection but may disrupt cellular architecture

  • Combination approaches (PFA followed by methanol permeabilization): May provide optimal balance

• Antigen retrieval considerations:

  • Heat-induced epitope retrieval in citrate buffer (pH 6.0) may improve signal for some tissues

  • Enzymatic retrieval is generally not recommended for nuclear proteins like POLR3H

• Blocking conditions:

  • 5% normal serum (from species of secondary antibody origin)

  • 3% BSA in PBS with 0.1% Triton X-100

• Antibody incubation:

  • Primary antibody dilution: 1:50-1:500, optimally at 1:100 for most applications

  • Overnight incubation at 4°C often yields superior results compared to shorter incubations

A431 cells have been validated as positive controls for POLR3H immunofluorescence applications .

How does POLR3H contribute to RNA polymerase III complex stability and function?

POLR3H (RPC8) functions as a specific peripheral component of RNA polymerase III, which is responsible for synthesizing small RNAs such as 5S rRNA and tRNAs . The RNA polymerase III complex consists of 17 subunits, with POLR3H interacting with CRCP/RPC9 to form a specific Pol III subcomplex .

Recent studies have begun to elucidate how subcellular localization affects RNA polymerase III fate and function . POLR3H's relatively small size (22.9 kDa) belies its importance in maintaining the structural integrity and proper function of the polymerase complex. Future research utilizing POLR3H antibodies will likely further clarify its precise structural role within the complex and how this contributes to polymerase function.

What insights have been gained from studying anti-POLR3H autoantibodies in cancer-associated scleroderma?

Research into anti-POLR3H autoantibodies has provided important insights into cancer-associated autoimmunity. In patients with scleroderma and anti-POLR3 autoantibodies, there's a significant association with cancer (particularly when cancer and scleroderma onset are temporally close) .

Studies have shown that approximately 91% of patients with anti-POLR3A antibodies also develop antibodies against POLR3H, suggesting extensive epitope spreading within the POLR3 complex . This contrasts with the limited detection (22%) of these antibodies using peptide-based methods, indicating the predominance of conformational epitopes.

A model of cancer-induced autoimmunity has emerged where mutations in POLR3A in cancer cells may serve as immunogens that initiate an immune response, which then spreads to target other components of the POLR3 complex including POLR3H . This pattern mirrors what has been observed in other paraneoplastic disorders where tumors drive autoimmunity.

These findings suggest that comprehensive testing for multiple POLR3 subunit antibodies, including POLR3H, may provide better diagnostic sensitivity for identifying cancer-associated scleroderma, potentially enabling earlier cancer detection and intervention.